AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9014909 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole‐cell cholera vaccine (two doses per person)
Number of subjects: 134453
Study 9014909 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete two‐dose vaccine regimen
Number of subjects: 134453
Study 9014909 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 134453
Study 8200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Lupron Depot 3.75 mg, intramuscularly monthly for three months)
Number of subjects: 30
Study 8200247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscularly monthly for three months)
Number of subjects: 30
Study 8200247 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 30
Study 3115779 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms min‐1 of GTN
Number of subjects: 7
Study 30042039 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Butyl Cyanoacrylate (NBCA)
Number of subjects: 525
Study 30042039 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 525
Study 30042039 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 525
Study 28139587 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adapting files system (SAF)
Number of subjects: 67
Study 28139587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic activation of irrigant
Number of subjects: 67
Study 28139587 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual tools
Number of subjects: 67
Study 25681041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils intubation fibrescope (BIF)
Number of subjects: 120
Study 25681041 — intervention group
Group type: COMPARATOR
Intervention: Tube introducer-assisted left molar (LM) laryngoscopy
Number of subjects: 120
Study 23232002 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) prophylaxis for 96 weeks
Number of subjects: 1351
Study 23232002 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 96 weeks
Number of subjects: 1351
Study 20937043 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 45
Study 20937043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20937043 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 45
Study 18764913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxygen therapy
Number of subjects: 30
Study 18764913 — intervention group
Group type: COMPARATOR
Intervention: Intranasal air
Number of subjects: 30
Study 17152347 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (600 mg orally once per day for 7 days)
Number of subjects: 12
Study 17152347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally once per day for 5 days)
Number of subjects: 12
Study 17152347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12
Study 17152347 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 12
Study 12603451 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 12603451 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study 15231966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.3 mg/kg once daily)
Number of subjects: 197
Study 15231966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 10195359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg given once daily for 2 weeks
Number of subjects: 201
Study 8995922 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for TMD (various interventions, specifics not provided)
Number of subjects: 1200
Study 8995922 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled observations (case series, case reports, etc.)
Number of subjects: 1200
Study 8995922 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment approaches
Number of subjects: 1200
Study 2357109 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric liaison nurse specialist consultation
Number of subjects: 107
Study 2357109 — intervention group
Group type: COMPARATOR
Intervention: No consultation (control group)
Number of subjects: 107
Study 307358 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (saphenous-vein bypass surgery)
Number of subjects: 130
Study 307358 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (propranolol therapy)
Number of subjects: 130
Study 307358 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 130
Study 307358 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 130
Study 29734923 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality group (VRG)
Number of subjects: 90
Study 29734923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutor-administered group (TAG)
Number of subjects: 90
Study 29734923 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (CG)
Number of subjects: 90
Study 31058772 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Protein Diet (EPD) with protein‐energy ratio 4 g/100 calories
Number of subjects: 36
Study 31058772 — intervention group
Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD) with protein‐energy ratio 3 g/100 calories
Number of subjects: 36
Study 31058772 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Protein Diet (EPD)
Number of subjects: 36
Study 31058772 — intervention group
Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD)
Number of subjects: 36
Study 28498927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin as bolus (100 mcg)
Number of subjects: 140
Study 28498927 — intervention group
Group type: COMPARATOR
Intervention: Carbetocin as short infusion (100 mcg)
Number of subjects: 140
Study 28498927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bolus and short infusion)
Number of subjects: 140
Study 25476156 — intervention group
Group type: COMPARATOR
Intervention: Standard dose radiography
Number of subjects: 288
Study 25476156 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% reduced dose radiography
Number of subjects: 288
Study 23970131 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (six times per week) in the daily trial
Number of subjects: 332
Study 23970131 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis (six times per week) in the nocturnal trial
Number of subjects: 332
Study 23970131 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (three times per week) in the daily trial
Number of subjects: 332
Study 23970131 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (three times per week) in the nocturnal trial
Number of subjects: 332
Study 21097567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Airway Management System (TAMS)
Number of subjects: 25
Study 21097567 — intervention group
Group type: COMPARATOR
Intervention: On-scene directed (OSD) group
Number of subjects: 25
Study 19167958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (GI) diet
Number of subjects: 23
Study 17079787 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for influenza
Number of subjects: 700
Study 17079787 — intervention group
Group type: COMPARATOR
Intervention: Standard testing (ST) for influenza
Number of subjects: 700
Study 15271701 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg/kg/h continuous infusion)
Number of subjects: 200
Study 15271701 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (0.1 mg/kg IV every 6 h)
Number of subjects: 200
Study 15271701 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 200
Study 15271701 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Ondansetron
Number of subjects: 200
Study 11578261 — intervention group
Group type: EXPERIMENTAL
Intervention: Single atrial cannulation
Number of subjects: 120
Study 11578261 — intervention group
Group type: EXPERIMENTAL
Intervention: Single atrial cannulation and intraoperative zero fluid balance hemofiltration
Number of subjects: 120
Study 11578261 — intervention group
Group type: COMPARATOR
Intervention: Bi-caval cannulation
Number of subjects: 120
Study 9228472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg intravenous loading dose, then 400 mg daily for four weeks (intravenous for at least 10 days)
Number of subjects: 106
Study 9228472 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 0.6 mg/kg/day (cumulative dose 8 mg/kg)
Number of subjects: 106
Study 9228472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 106
Study 9228472 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 106
Study 7962885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue Exposure (CE) treatment with 400 min exposure to the sight and smell of preferred drinks over 10 days
Number of subjects: 35
Study 7962885 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Control (RC) treatment with 20 min exposure to alcohol cues
Number of subjects: 35
Study 29596904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 19
Study 26908565 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 63
Study 26908565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 24074849 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (placebo-controlled)
Number of subjects: 0
Study 24074849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23733031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary flaxseed supplementation (30 g total, in 2 muffins and 1 slice of bread daily)
Number of subjects: 32
Study 20626325 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 600 mg/day) with cisplatin
Number of subjects: 54
Study 20626325 — intervention group
Group type: EXPERIMENTAL
Intervention: salicylate (300 mg/day) with cisplatin
Number of subjects: 54
Study 20626325 — intervention group
Group type: COMPARATOR
Intervention: cisplatin
Number of subjects: 54
Study 19128716 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaystar transducers
Number of subjects: 9
Study 19128716 — intervention group
Group type: COMPARATOR
Intervention: Computerized dynamic posturography (CDP)
Number of subjects: 9
Study 17162430 — intervention group
Group type: COMPARATOR
Intervention: Calcium Acetate
Number of subjects: 70
Study 17162430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride
Number of subjects: 70
Study 12830065 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin autotransfusion (group H)
Number of subjects: 144
Study 12830065 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate autotransfusion (group C)
Number of subjects: 144
Study 12830065 — intervention group
Group type: COMPARATOR
Intervention: Control group (N)
Number of subjects: 144
Study 10980459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 0
Study 10980459 — intervention group
Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 0
Study 8871794 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual behavioural-cognitive therapy
Number of subjects: 27
Study 8871794 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 27
Study 1627968 — intervention group
Group type: COMPARATOR
Intervention: Buspirone (20-100 mg/day for 4 weeks)
Number of subjects: 22
Study 1627968 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (40-100 mg/day for 3 weeks)
Number of subjects: 22
Study 6585372 — intervention group
Group type: EXPERIMENTAL
Intervention: Double headed toothbrush
Number of subjects: 39
Study 6585372 — intervention group
Group type: COMPARATOR
Intervention: Single headed toothbrush with modified Bass technique
Number of subjects: 39
Study 6585372 — intervention group
Group type: COMPARATOR
Intervention: Single headed toothbrush with modified Bass and roll techniques
Number of subjects: 39
Study 31320353 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised adherence intervention (XPAND)
Number of subjects: 24
Study 31320353 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 24
Study 29346503 — intervention group
Group type: EXPERIMENTAL
Intervention: High p53β expression
Number of subjects: 266
Study 29346503 — intervention group
Group type: COMPARATOR
Intervention: p53 wild-type
Number of subjects: 266
Study 29346503 — intervention group
Group type: EXPERIMENTAL
Intervention: p53β transfected 786-O and CAKi-1 cells
Number of subjects: 266
Study 27184664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio First Angel™ CPR feedback device
Number of subjects: 80
Study 27184664 — intervention group
Group type: COMPARATOR
Intervention: Standard manual CPR
Number of subjects: 80
Study 25413974 — intervention group
Group type: EXPERIMENTAL
Intervention: Safeguarding Children Assessment and Analysis Framework (SAAF)
Number of subjects: 6
Study 25413974 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 6
Study 22217004 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial resection of the distal sac and suture ligation at the neck (Group I)
Number of subjects: 50
Study 22217004 — intervention group
Group type: COMPARATOR
Intervention: Suture ligation at the neck (Group II)
Number of subjects: 50
Study 20868800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic conditioning of the gastric conduit (laparoscopic gastrolysis)
Number of subjects: 19
Study 18081861 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 0
Study 18081861 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap operation
Number of subjects: 0
Study 18081861 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Protein Derivatives (EMD)
Number of subjects: 0
Study 18081861 — intervention group
Group type: COMPARATOR
Intervention: Control group (flap operation)
Number of subjects: 0
Study 16055826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 20
Study 16055826 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent procedure
Number of subjects: 20
Study 12108557 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC)
Number of subjects: 0
Study 12108557 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC) combined with frequent outpatient mental health services
Number of subjects: 0
Study 12108557 — intervention group
Group type: EXPERIMENTAL
Intervention: Case managers' verbal reminders about consequences of nonadherence to treatment
Number of subjects: 0
Study 10663897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinedefecography evidence of difficult evacuation (Group 1)
Number of subjects: 185
Study 10663897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinedefecography evidence of difficult evacuation with rectocele (Group 1)
Number of subjects: 185
Study 10663897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinedefecography evidence of difficult evacuation with intussusception (Group 1)
Number of subjects: 185
Study 10663897 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment for patients with rectocele (Group 1)
Number of subjects: 185
Study 8578808 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐TV (rhesus tetravalent rotavirus vaccine)
Number of subjects: 0
Study 8578808 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐S1 (serotype 1 monovalent rotavirus vaccine)
Number of subjects: 0
Study 8578808 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐TV
Number of subjects: 0
Study 8578808 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐S1
Number of subjects: 0
Study 8578808 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV vaccines
Number of subjects: 0
Study 2190565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 0
Study 2190565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 414613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 mg sublingually)
Number of subjects: 11
Study 414613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30916035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 110
Study 30916035 — intervention group
Group type: COMPARATOR
Intervention: Control ventilation
Number of subjects: 110
Study 29781640 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory depletion task
Number of subjects: 24
Study 29781640 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 24
Study 26578353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SMC with sulphadoxine-pyrimethamine and amodiaquine plus AL for case management
Number of subjects: 2400
Study 26578353 — intervention group
Group type: COMPARATOR
Intervention: Placebo SMC plus AL for case management
Number of subjects: 2400
Study 26578353 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting ACT (dihydroartemisinin-piperaquine, DP) for case management
Number of subjects: 2400
Study 25266831 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens aphakic correction
Number of subjects: 114
Study 25266831 — intervention group
Group type: COMPARATOR
Intervention: Intraocular lens (IOL) placement
Number of subjects: 114
Study 22192640 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI remifentanil
Number of subjects: 36
Study 22192640 — intervention group
Group type: COMPARATOR
Intervention: TCI propofol
Number of subjects: 36
Study 20946141 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian Medical Sheepskin (AMS) as a layer on the mattress, applied within 48 hours after admission, alongside usual care.
Number of subjects: 588
Study 20946141 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 588
Study 20946141 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian Medical Sheepskin (AMS) with adjustment for Braden risk score, age, and gender.
Number of subjects: 588
Study 17293228 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor (GM-CSF) 250 microg/m2, subcutaneous injection, 3 times a week
Number of subjects: 121
Study 17293228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 16573802 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily plus Aspirin 325 mg once daily (E40 b.d. + A325)
Number of subjects: 45
Study 16573802 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily plus Rofecoxib 25 mg once daily (E40 b.d. + R25)
Number of subjects: 45
Study 16573802 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily (E40 b.d.)
Number of subjects: 45
Study 16573802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily (R25)
Number of subjects: 45
Study 16573802 — intervention group
Group type: COMPARATOR
Intervention: Control group (Esomeprazole 40 mg b.d. and Rofecoxib 25 mg once daily)
Number of subjects: 45
Study 12796713 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.72% sodium lactate infusion at a rate of 50 micro mol. kg‐1. min‐1 for 20 minutes, then reduced to 30 micro mol. kg‐1. min‐1
Number of subjects: 8
Study 12796713 — intervention group
Group type: COMPARATOR
Intervention: 1.4% sodium bicarbonate infusion
Number of subjects: 8
Study 10352333 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg aspirin daily for 7 days
Number of subjects: 20
Study 7588683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion (artificially sweetened, coloured water), mean 1.49 L consumed, mean 1.02 L available after accounting for stomach retention and urination
Number of subjects: 8
Study 7588683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion (artificially sweetened, coloured water)
Number of subjects: 8
Study 7588683 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 8
Study 1742818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg‐1 and midazolam 0.2 mg.kg‐1 (Group I)
Number of subjects: 20
Study 1742818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg‐1 and midazolam 0.4 mg.kg‐1 (Group II)
Number of subjects: 20
Study 1742818 — intervention group
Group type: COMPARATOR
Intervention: Higher dose of midazolam (0.4 mg.kg‐1)
Number of subjects: 20
Study 7056975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy consisting of estrogen, fluoride, and calcium
Number of subjects: 9
Study 7056975 — intervention group
Group type: COMPARATOR
Intervention: Fluoride and calcium without estrogen (Control)
Number of subjects: 9
Study 31479009 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR athletes
Number of subjects: 42
Study 31479009 — intervention group
Group type: COMPARATOR
Intervention: Uninjured controls
Number of subjects: 42
Study 28965476 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 35
Study 28965476 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 35
Study 27880977 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass surgery
Number of subjects: 100
Study 27880977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 100
Study 25840501 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TELE)
Number of subjects: 197
Study 25840501 — intervention group
Group type: COMPARATOR
Intervention: Home-visit rehabilitation (VISIT)
Number of subjects: 197
Study 24175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Castrated prostatic cancer patients (group III)
Number of subjects: 247
Study 24175566 — intervention group
Group type: COMPARATOR
Intervention: Non-castrated prostatic cancer patients (group II)
Number of subjects: 247
Study 24175566 — intervention group
Group type: COMPARATOR
Intervention: Non-prostatic cancer patients (group I)
Number of subjects: 247
Study 21128876 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 20